510(k) Report

510(k) · Cleared

Cleared

Paxerapacs

K132586510(k) TraditionalCleared Oct 31, 201376-day reviewClass II21 CFR 892.2050

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Paxeramed · LLZ System, Image Processing, Radiological

Cleared on Oct 31, 2013 after a 76-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Oct 31, 2013
Review
76 days
Class
Class II
Product code
LLZ
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K132586Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LLZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LLZ device

  1. #1 K230955 syngo Application Softwarescore 21.5 · 11 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All LLZ devices

LLZ System, Image Processing, Radiological: FDA decisions, review times, recalls and adverse event reports over 20 years. 2013, this device’s year, is highlighted.

FDA decisions per year · LLZ

58in 2025

2007: 762008: 942009: 702010: 512011: 1062012: 822013: 952014: 782015: 642016: 822017: 782018: 1042019: 742020: 812021: 832022: 652023: 872024: 622025: 582026 (partial year): 45
2007high 106 (2011) · low 51 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LLZ

173in 2025

2007: 36 days median2008: 52 days median2009: 62 days median2010: 98 days median2011: 79 days median2012: 87 days median2013: 84 days median2014: 89 days median2015: 90 days median2016: 90 days median2017: 107 days median2018: 105 days median2019: 107 days median2020: 115 days median2021: 116 days median2022: 137 days median2023: 157 days median2024: 131 days median2025: 173 days median2026 (partial year): 110 days median
2007high 173 (2025) · low 36 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LLZ

11in 2025

2007: 202008: 322009: 212010: 172011: 302012: 122013: 642014: 62015: 162016: 122017: 52018: 72019: 22020: 62021: 32022: 42023: 82024: 62025: 112026 (partial year): 14
2007high 64 (2013) · low 2 (2019)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LLZ

116in 2025

2007: 1522008: 1542009: 1452010: 1452011: 4542012: 2662013: 1,1302014: 15,6312015: 2112016: 2902017: 1042018: 722019: 882020: 822021: 702022: 282023: 262024: 422025: 116
2007high 15,631 (2014) · low 26 (2023)2025

MAUDE reports naming product code LLZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007763620152
2008945232154
2009706221145
2010519817145
20111067930454
2012828712266
20139584641,130
20147889615,631
2015649016211
2016829012290
2017781075104
2018104105772
201974107288
202081115682
202183116370
202265137428
202387157826
202462131642
20255817311116
20264511014—

What is it indicated for?

The Paxera PALS is a scalable medical image and informatics system intended to receive, transmit, display, print and process digital images from medical image modality supporting the DICOM 3.0 standard, these modalities are Magnetic Resonance (MR), Computed Tomography (CT) Computed Radiography (CR), Digital X-Ray (DR), Digital Mammography (MG), X-Ray Angiography (XA), Ultrasound (US), Nuclear Medicine (NM), and Positron Emission Tomography (PT). The…

Read the full statement (275 words)

The Paxera PALS is a scalable medical image and informatics system intended to receive, transmit, display, print and process digital images from medical image modality supporting the DICOM 3.0 standard, these modalities are Magnetic Resonance (MR), Computed Tomography (CT) Computed Radiography (CR), Digital X-Ray (DR), Digital Mammography (MG), X-Ray Angiography (XA), Ultrasound (US), Nuclear Medicine (NM), and Positron Emission Tomography (PT).

The Paxera PACS workstation provides the user with the ability to display, manipulate, attach diagnostic reports, archive, transmit and print images using DICOM and other computer industry standard interfaces and standards.

Mammography images intended for primary interpretation must be acquired for an FDA approved Full Field Digital Mammography (FDDM) device. In addition, the FDDM device must be able to provide to the Paxera PALS "for presentation" a viewable DICOM image as approved by FDA for primary interpretation. If images are sent to a film printer such printers must be FDA approved for diagnosis of digital mammography images. If digital mammography images are viewed on a display that display must be cleared by the FDA for primary diagnosis of digital mammography images.

The Paxera PACS allows for integration with many open interfaces including DICOM, Web Client, and Archiving devices. The Paxera PACS server infrastructure software facilitate database management and image management, printing, HL-7 interfacing and all DICOM services such as Store/Retrieve, Query and Send.

The Paxera PACS is intended for use by trained medical professionals including but not limited to, Radiologists, Physicians and Medical Technologists. It is the user's responsibility to ensure quality by taking measures to achieve the proper lighting conditions and image compression ratios consistent with the clinical requirements of the indented use.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K132586: Paxerapacs.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K132586

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026